Journal of Southern Medical University ›› 2024, Vol. 44 ›› Issue (11): 2156-2162.doi: 10.12122/j.issn.1673-4254.2024.11.12

Previous Articles    

Liuwei Buqi Formula delays progression of chronic obstructive pulmonary disease in rats by regulating the NLRP3/caspase-1/GSDMD pyroptosis pathway

Li MEI1(), Lu ZHANG1, Di WU1, Huanzhang DING1, Xinru WANG1,2, Xian ZHANG1,2, Yuhang WEI1, Zegeng LI2,3,4, Jiabing TONG2,3,4()   

  1. 1.Graduate School of Anhui University of Traditional Chinese Medicine, Hefei 230012, China
    2.First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China
    3.Xin'an Institute of Medicine and Modernization of Traditional Chinese Medicine, Institute of Health Research, Hefei National Science Center, Hefei 230012, China
    4.Anhui Provincial Key Laboratory of Application and Transformation of Traditional Chinese Medicine in Prevention and Treatment of Major Pulmonary Diseases, Hefei 230031, China
  • Received:2024-03-15 Online:2024-11-20 Published:2024-11-29
  • Contact: Jiabing TONG E-mail:ml13505595702@163.com;tjbahzy@sina.com
  • Supported by:
    National Natural Science Foundation of China(82374399)

Abstract:

Objective To explore the therapeutic mechanism of Liuwei Buqi (LWBQ) Formula for chronic obstructive pulmonary disease (COPD) in rat models. Methods SD rat models of COPD established by cigarette smoking combined with intratracheal lipopolysaccharide (LPS) instillation and hormone injection were treated with LWBQ Formula by gavage with or without intraperitoneal injection of MCC950 for 3 weeks, starting at the 5th week of modeling. After the treatments, the rats were examined for lung pathologies, lung function, total cell count and white blood cell count in bronchoalveolar lavage fluid (BALF), and serum levels of IL-6, TNF-α, IL-18 and NO. The mRNA expressions of NLRP3, ASC, caspase-1, GSDMD-N, IL-1β, and IL-18 in the lung tissue were detected with qRT-PCR. Results Compared with the normal control rats, the COPD rat models had severe lung pathologies and showed significantly decreased lung function, increased total cell and leukocyte subset counts in BALF, and increased serum levels of IL-6, TNF-α, IL-18 and NO and mRNA expressions of pyroptosis-related proteins in the lung tissue. Treatment of the rat models with LWBQ Formula significantly improved lung pathology and lung function, reduced total cell and leukocyte counts in BALF, and decreased serum levels of the inflammatory factors and expressions of pyroptosis-related proteins in the lung tissue. The combined treatment with MCC950 further improved lung pathology and function in spite of a significant difference, but BALF cell counts, serum inflammatory factor levels and pulmonary expressions of pyroptosis-related proteins were all significantly reduced following the treatment. Conclusion LWBQ Formula can delay the progression of COPD in rats possibly by inhibiting lung tissue pyroptosis via regulating the NLRP3/caspase-1/GSDMD pathway to reduce inflammatory response and lung damage.

Key words: Liuwei Buqi Formula, chronic obstructive pulmonary disease, NLRP3/caspase-1/GSDMD, pyroptosis, MCC950